Evidence map›Paper›PMID 26393116›Full record

ArticleJournal of clinical and diagnostic research : JCDR2015

Emerging Role of Myeloperoxidase in the Prognosis of Nephrotic Syndrome Patients Before and After Steroid Therapy.

Sreelatha Souparnika, Benedicta D'Souza, Vivian D'Souza, Sushanth Kumar, Poornima Manjrekar, Manohar Bairy, Rajeevalochana Parthasarathy, Srinivas Kosuru

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and diagnostic research : JCDR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Myeloperoxidase as a therapeutic target for oxidative damage in Alzheimer's disease.Journal of enzyme inhibition and medicinal chemistry · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sreelatha SouparnikaSenior Research Fellow, Department of Biochemistry, Kasturba Medical College , Mangalore, Manipal University, India .
Benedicta D'SouzaProfessor, Department of Biochemistry, Kasturba Medical College , Mangalore, Manipal University, India .
Vivian D'SouzaProfessor, Department of Biochemistry, Kasturba Medical College , Mangalore, Manipal University, India .
Sushanth KumarAssociate Professor, Department of Nephrology, Kasturba Medical College , Mangalore, Manipal University, India .
Poornima ManjrekarProfessor and Head, Department of Biochemistry, Kasturba Medical College , Mangalore, Manipal University, India .
Manohar BairyAssociate Professor, Department of Nephrology, Kasturba Medical College , Mangalore, Manipal University, India .
Rajeevalochana ParthasarathyPost Graduate, Department of Nephrology, Kasturba Medical College , Mangalore, Manipal University, India .
Srinivas KosuruPost Graduate, Department of Nephrology, Kasturba Medical College , Mangalore, Manipal University, India .
Kasturba Medical College, Manipal · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyeloperoxidase (MPO) is a myelocyte derived iron containing enzyme particularly involved in host defense by destroying foreign micro organisms invading the body. Numerous evidences suggest that MPO is involved in the pathogenesis of many inflammatory diseases, especially atherosclerosis.

aimPresent study deals with the role of MPO in the renal function and progression of disease in Nephrotic syndrome patients. STUDY DESIGN AND SETTINGS: Case- Control Study carried out in Kasturba Medical College Hospital, Mangalore, India. MATERIALS AND

methodsForty newly diagnosed Nephrotic syndrome cases, 40 age and sex matched healthy controls and 15 subjects in Nephrotic syndrome remission, were included in the study. Myeloperoxidase enzyme was assayed by 4 amino antipyrine methods in all the subjects. Other renal parameters like urea, creatinine, Blood Urea Nitrogen (BUN), BUN- Creatinine ratio (BUN/Cr) total protein, albumin, globulin, albumin - globulin ratio (A/G ratio) and estimated Glomerular Filtration Rate (eGFR) were also analysed. 24 hour urine protein-creatinine ratio was estimated in Nephrotic syndrome cases and remission group by turbidimetric assay. STATISTICAL ANALYSIS: Students paired t-test and Wilcoxon Signed Rank test were used for the comparison of the data. Pearson and Spearman analyses were used for correlation of the parameters.

resultsMPO levels were found to be high in Nephrotic syndrome cases when compared to healthy controls. Urea, creatinine, BUN, BUN/Cr ratio and eGFR were high in Nephrotic syndrome cases while total protein, albumin, globulin and A/G ratio showed decreased levels. MPO had a positive correlation with creatinine and urine protein-creatinine ratio in Nephrotic syndrome. During remission, MPO levels decreased significantly while total protein and albumin levels increased.

conclusionMyeloperoxidase enzyme is found to be elevated and it strongly correlated with the severity of disease in Nephrotic syndrome. Further studies can be done to use MPO as a therapeutic target in Nephrotic syndrome to ameliorate the symptoms.

Indexed as

Nephrotic SyndromeProtein-creatinine ratioRemission

Identifiers

PMID26393116
PMCPMC4572946
OpenAlexW2342139291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.